{'fraction_non_alphanumeric': 0.042068361086765996, 'fraction_numerical': 0.020157756354075372, 'mean_word_length': 5.074468085106383, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression.

Motility of malignant cells plays a crucial role for the metastasis of tumours. Both, 17-beta-estradiol and transforming growth factor-beta (TGF-beta), induce migration of MCF-7 breast cancer cells and simultaneous treatment resulted in an additive effect of the migratory response. But most interestingly, when cells were preincubated with 17-beta-estradiol, the ability of TGF-beta to evoke chemotaxis was drastically diminished. Abrogation of Smad signalling indicated that this pathway is essential for TGF-beta-mediated MCF-7 cell migration. In agreement, pretreatment of MCF-7 cells with 17-beta-estradiol resulted in a reduced phosphorylation of Smad2 and Smad3 as well as a diminished Smad2 and Smad3 gene reporter activity in response to TGF-beta. Thus, these results indicate a controversial role of 17-beta-estradiol on MCF-7 cell migration. 17-Beta-estradiol potently increases the migratory potency of MCF-7 cells, but inhibits TGF-beta-induced migration by an interaction between estrogen receptors and Smad proteins.